drugset / Trial / NCT00002225

A Study of Efavirenz in Combination With Stavudine and Didanosine

NCT00002225

Phase 2 Completed 60 enrolled Dupont Merck
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus didanosine to HIV-infected patients who have never received anti-HIV treatment.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule
Subject Efavirenz Other / unclassified
Subject Stavudine Other / unclassified